Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Lipigon Pharmaceuticals

0.01 SEK

-87.42 %

Less than 1K followers

LPGO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-87.42 %
-88.07 %
-93.18 %
-88.07 %
-86.90 %
-91.12 %
-98.37 %
-
-99.80 %

Lipigon Pharmaceuticals operates in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio is broad and includes drugs for rare diseases. These are primarily treatments for diseases caused by disorders in the body's handling of fats. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market.

Read more
Market cap
7.03M SEK
Turnover
2.18M SEK
Revenue
10.29M
EBIT %
-248.59 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/3
2026

Annual report '25

14/5
2026

Interim report Q1'26

25/8
2026

Interim report Q2'26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Press release20 hours ago

Investor Studios: Lipigon Pharmaceuticals VD & CMO presenterar live 15.00

Lipigon Pharmaceuticals
Press releaseyesterday

Lipigon Pharmaceuticals bjuder in till webbsänd presentation av top line-resultat i den pågående kliniska fas II-studien

Lipigon Pharmaceuticals
Regulatory press releaseyesterday

Lipigon Pharmaceuticals presenterar top line-data från den kliniska fas II-studien av Lipisense i patienter med förhöjda blodfettsnivåer

Lipigon Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press releaseyesterday

Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels

Lipigon Pharmaceuticals
Press release11/25/2025, 3:15 PM

Lipigon Pharmaceuticals valberedning utsedd inför Lipigons årsstämma 2026

Lipigon Pharmaceuticals
Press release11/21/2025, 11:19 AM

Redeye: Lipigon (Q3 Review) - Topline Before Year-End

Lipigon Pharmaceuticals
Regulatory press release11/20/2025, 7:00 AM

Lipigon publicerar delårsrapport för januari - september 2025

Lipigon Pharmaceuticals
Regulatory press release10/21/2025, 12:59 PM

Lipigon utser Redeye AB till ny Certified Adviser

Lipigon Pharmaceuticals
Press release10/14/2025, 8:58 PM

Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense

Lipigon Pharmaceuticals
Press release10/14/2025, 8:58 PM

Lipigon Pharmaceuticals rapporterar sista patientbesöket i tremånadersuppföljningen i bolagets kliniska fas II-studie med Lipisense

Lipigon Pharmaceuticals
Press release9/9/2025, 1:10 PM

Lipigon Pharmaceuticals vd Johan Liwing deltar i panelsamtal vid LSX World Congress USA 2025

Lipigon Pharmaceuticals
Press release8/26/2025, 12:28 PM

Redeye: Lipigon Q2 2025 - Last Patient In

Lipigon Pharmaceuticals
Regulatory press release8/26/2025, 6:00 AM

Lipigon publicerar delårsrapport för januari - juni 2025

Lipigon Pharmaceuticals
Regulatory press release8/22/2025, 7:25 AM

Lipigon Pharmaceuticals meddelar förändringar i ledningsgruppen

Lipigon Pharmaceuticals
Press release7/28/2025, 6:50 AM

Lipigon Pharmaceuticals vd köper teckningsoptioner

Lipigon Pharmaceuticals
Regulatory press release7/6/2025, 7:03 AM

Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®

Lipigon Pharmaceuticals
Regulatory press release6/26/2025, 5:03 PM

Kommuniké från årsstämma 2025 i Lipigon Pharmaceuticals AB den 26 juni 2025

Lipigon Pharmaceuticals
Regulatory press release6/23/2025, 1:51 PM

Lipigon Pharmaceuticals inkluderar sista patienten till den kliniska fas II-studien med Lipisense

Lipigon Pharmaceuticals
Regulatory press release6/13/2025, 4:05 PM

Sista dag för handel med BTA i Lipigon - omvandling av BTA till aktier

Lipigon Pharmaceuticals
Regulatory press release6/4/2025, 6:56 PM

Lipigon publicerar årsredovisning för 2024

Lipigon Pharmaceuticals
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.